The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment
It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yang, Jiyuan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering - Liu, Yansheng ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:31 ; year:2017 ; pages:30-42 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cocis.2017.07.003 |
|---|
| Katalog-ID: |
ELV030709334 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030709334 | ||
| 003 | DE-627 | ||
| 005 | 20230625182504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cocis.2017.07.003 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000034.pica |
| 035 | |a (DE-627)ELV030709334 | ||
| 035 | |a (ELSEVIER)S1359-0294(17)30056-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 540 | |
| 082 | 0 | 4 | |a 540 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 51.79 |2 bkl | ||
| 084 | |a 35.48 |2 bkl | ||
| 100 | 1 | |a Yang, Jiyuan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. | ||
| 520 | |a It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. | ||
| 700 | 1 | |a Kopeček, Jindřich |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Liu, Yansheng ELSEVIER |t Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV003906671 |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g pages:30-42 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cocis.2017.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 51.79 |j Sonstige Werkstoffe |q VZ |
| 936 | b | k | |a 35.48 |j Sonstige anorganische Elemente und ihre Verbindungen |q VZ |
| 951 | |a AR | ||
| 952 | |d 31 |j 2017 |h 30-42 |g 13 | ||
| 953 | |2 045F |a 540 | ||
| author_variant |
j y jy |
|---|---|
| matchkey_str |
yangjiyuankopeekjindich:2017----:hlgtthedfhtnescngnrtohmcnua |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
51.79 35.48 |
| publishDate |
2017 |
| allfields |
10.1016/j.cocis.2017.07.003 doi GBV00000000000034.pica (DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 DE-627 ger DE-627 rakwb eng 540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl Yang, Jiyuan verfasserin aut The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment 2017transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. Kopeček, Jindřich oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:31 year:2017 pages:30-42 extent:13 https://doi.org/10.1016/j.cocis.2017.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 31 2017 30-42 13 045F 540 |
| spelling |
10.1016/j.cocis.2017.07.003 doi GBV00000000000034.pica (DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 DE-627 ger DE-627 rakwb eng 540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl Yang, Jiyuan verfasserin aut The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment 2017transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. Kopeček, Jindřich oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:31 year:2017 pages:30-42 extent:13 https://doi.org/10.1016/j.cocis.2017.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 31 2017 30-42 13 045F 540 |
| allfields_unstemmed |
10.1016/j.cocis.2017.07.003 doi GBV00000000000034.pica (DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 DE-627 ger DE-627 rakwb eng 540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl Yang, Jiyuan verfasserin aut The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment 2017transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. Kopeček, Jindřich oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:31 year:2017 pages:30-42 extent:13 https://doi.org/10.1016/j.cocis.2017.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 31 2017 30-42 13 045F 540 |
| allfieldsGer |
10.1016/j.cocis.2017.07.003 doi GBV00000000000034.pica (DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 DE-627 ger DE-627 rakwb eng 540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl Yang, Jiyuan verfasserin aut The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment 2017transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. Kopeček, Jindřich oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:31 year:2017 pages:30-42 extent:13 https://doi.org/10.1016/j.cocis.2017.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 31 2017 30-42 13 045F 540 |
| allfieldsSound |
10.1016/j.cocis.2017.07.003 doi GBV00000000000034.pica (DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 DE-627 ger DE-627 rakwb eng 540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl Yang, Jiyuan verfasserin aut The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment 2017transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. Kopeček, Jindřich oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:31 year:2017 pages:30-42 extent:13 https://doi.org/10.1016/j.cocis.2017.07.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 31 2017 30-42 13 045F 540 |
| language |
English |
| source |
Enthalten in Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering Amsterdam [u.a.] volume:31 year:2017 pages:30-42 extent:13 |
| sourceStr |
Enthalten in Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering Amsterdam [u.a.] volume:31 year:2017 pages:30-42 extent:13 |
| format_phy_str_mv |
Article |
| bklname |
Sonstige Werkstoffe Sonstige anorganische Elemente und ihre Verbindungen |
| institution |
findex.gbv.de |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| authorswithroles_txt_mv |
Yang, Jiyuan @@aut@@ Kopeček, Jindřich @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003906671 |
| dewey-sort |
3540 |
| id |
ELV030709334 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030709334</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625182504.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cocis.2017.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000034.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030709334</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-0294(17)30056-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.79</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.48</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Jiyuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopeček, Jindřich</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liu, Yansheng ELSEVIER</subfield><subfield code="t">Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV003906671</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:30-42</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cocis.2017.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.79</subfield><subfield code="j">Sonstige Werkstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.48</subfield><subfield code="j">Sonstige anorganische Elemente und ihre Verbindungen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2017</subfield><subfield code="h">30-42</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| author |
Yang, Jiyuan |
| spellingShingle |
Yang, Jiyuan ddc 540 bkl 51.79 bkl 35.48 The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| authorStr |
Yang, Jiyuan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003906671 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| topic |
ddc 540 bkl 51.79 bkl 35.48 |
| topic_unstemmed |
ddc 540 bkl 51.79 bkl 35.48 |
| topic_browse |
ddc 540 bkl 51.79 bkl 35.48 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j k jk |
| hierarchy_parent_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| hierarchy_parent_id |
ELV003906671 |
| dewey-tens |
540 - Chemistry |
| hierarchy_top_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003906671 |
| title |
The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| ctrlnum |
(DE-627)ELV030709334 (ELSEVIER)S1359-0294(17)30056-0 |
| title_full |
The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| author_sort |
Yang, Jiyuan |
| journal |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| journalStr |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
30 |
| author_browse |
Yang, Jiyuan |
| container_volume |
31 |
| physical |
13 |
| class |
540 540 DE-600 540 VZ 51.79 bkl 35.48 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yang, Jiyuan |
| doi_str_mv |
10.1016/j.cocis.2017.07.003 |
| dewey-full |
540 |
| title_sort |
light at the end of the tunnel—second generation hpma conjugates for cancer treatment |
| title_auth |
The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| abstract |
It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. |
| abstractGer |
It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. |
| abstract_unstemmed |
It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment |
| url |
https://doi.org/10.1016/j.cocis.2017.07.003 |
| remote_bool |
true |
| author2 |
Kopeček, Jindřich |
| author2Str |
Kopeček, Jindřich |
| ppnlink |
ELV003906671 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.cocis.2017.07.003 |
| up_date |
2024-07-06T18:17:02.373Z |
| _version_ |
1803854620785639424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030709334</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625182504.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cocis.2017.07.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000034.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030709334</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-0294(17)30056-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.79</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.48</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Jiyuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The light at the end of the tunnel—second generation HPMA conjugates for cancer treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is almost four decades since N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers arose as drug carriers. Although fundamentals have been established and significant advantages have been proved, the commercialization of this platform technology was hampered due to modest outcome of clinical trial initiated with PK1, the symbol of first generation polymer-drug conjugates. In this review, we illustrate the exciting progress and approaches offered by more effective 2nd generation HPMA-based polymer-drug conjugates in cancer treatment. For example, a new synthetic strategy endorses inert HPMA polymer with biodegradability, which permitted to prepare high molecular weight HPMA-drug conjugates with simple linear architecture while maintaining good biocompatibility. As expected, extended long-circulating pharmacokinetics and enhanced antitumor activities were achieved in several preclinical investigations. In addition, greater inhibition of tumor growth in combination regimes exhibits the remarkable capability and flexibility of HPMA-based macromolecular therapeutics. The review also discusses the main challenges and strategies for further translation development of 2nd generation HPMA-based polymer-drug conjugates.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopeček, Jindřich</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liu, Yansheng ELSEVIER</subfield><subfield code="t">Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV003906671</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:30-42</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cocis.2017.07.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.79</subfield><subfield code="j">Sonstige Werkstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.48</subfield><subfield code="j">Sonstige anorganische Elemente und ihre Verbindungen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2017</subfield><subfield code="h">30-42</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| score |
7.3997936 |